STOCK TITAN
  1. Home
  2. News
  3. OPTHF

Optimi Health Corp - OPTHF STOCK NEWS

Welcome to our dedicated news page for Optimi Health (Ticker: OPTHF), a resource for investors and traders seeking the latest updates and insights on Optimi Health.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Optimi Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Optimi Health's position in the market.

News
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research
Rhea-AI Summary
Optimi Health Corp. partners with Kwantlen Polytechnic University Applied Genomics Centre to advance mushroom science and research. The project aims to genetically identify psilocybin-containing mushrooms, leveraging Optimi's extensive genetic bank. This collaboration seeks to enhance DNA characterization for clinical trials and medicinal activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.38%
Tags
partnership
-
News
Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
Rhea-AI Summary
Optimi Health Corp. completes in-house production of MDMA Active Pharmaceutical Ingredient (API) from raw materials under Precursor Licence. Three batches tested and validated by third-party laboratory. Company's distinctive advantage with in-house production highlighted. CEO Bill Ciprick emphasizes quality assurance standards and client collaboration. Chief Operations Officer Bryan Safarik reports over 60 grams of MDMA API produced. Company's expertise showcased at upcoming conference in Boston.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
none
-
News
Optimi Health Signs Psilocybin Supply Agreement With New Zealand-Based Mātai Medical Research Institute
Rhea-AI Summary
Optimi Health Corp. signs a natural psilocybin supply agreement with Mātai Medical Research Institute, marking its first deal in New Zealand. The agreement includes providing GMP Full Spectrum Natural Psilocybin extract to Mātai for the Tū Wairua Project's clinical trial. Optimi recently received COA for three validation batches, showcasing high-quality standards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.4%
Tags
none
News
Optimi Health Receives Finished Product Test Results and Certificate Of Analysis for GMP Natural Psilocybin Extract
Rhea-AI Summary
Optimi Health Corp. completes in-house encapsulation of psilocybin extract in 5mg and 10mg dosage formats. Third-party testing confirms compliance with GMP specifications and potency levels. The company progresses towards human consumption release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Optimi Health Confirms Presenting Sponsorship at the 4th Annual Psychedelic Therapeutics and Drug Development Conference
Rhea-AI Summary
Optimi Health Corp. announces its role as a Presenting Sponsor at the 4th Annual Psychedelic Therapeutics and Drug Development Conference. CEO Bill Ciprick will speak on the future of GMP psychedelic manufacturing. The event aims to explore the challenges and opportunities in developing psychedelic therapies. Optimi aims to showcase its strength as a top GMP psychedelics manufacturer committed to quality and safety standards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.62%
Tags
none
-
News
Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University
Rhea-AI Summary
Optimi Health Corp. signs its first international MDMA supply agreement with The Institute for Psychedelic Research at Tel Aviv University, marking its entry into the Israeli market. The collaboration aims to support research on the effects of MDMA on alcohol addiction in animal models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.25%
Tags
none
News
Optimi Announces Closing of First Tranche of Non-Brokered Private Placement
Rhea-AI Summary
Optimi Health Corp. closed the first tranche of a private placement, led by co-founders JJ Wilson and Dane Stevens, raising CAD$555,010. The company issued 1,850,033 units at CAD$0.30 per unit. Each unit consists of a common share and a warrant. The proceeds will be used to obtain a Drug Establishment License, facilitate commercialization, and for general working capital. Founders committed to a one-year lock-up period for their shares, showing dedication to commercializing the business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.55%
Tags
none
-
News
Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video
Rhea-AI Summary
Optimi Health Corp. congratulates Lykos Therapeutics on FDA's acceptance of NDA for PTSD therapy. Optimi showcases GMP MDMA production process. FDA's priority review highlights the potential breakthrough in mental healthcare. Optimi aligns with Lykos protocol for MDMA encapsulation. Optimi emphasizes commitment to quality assurance and transparency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.79%
Tags
none
-
News
Optimi Announces Non-Brokered Private Placement
Rhea-AI Summary
Optimi Health Corp. announces a non-brokered private placement of up to 5,000,000 units at CAD$0.30 per unit, with gross proceeds of up to CAD$1,500,000. The company intends to use the net proceeds to obtain its Drug Establishment License, commercialization, and for general working capital. Insiders of the company may participate in the offering for up to $605,000. The issuance of units to insiders will be considered a 'related party transaction'. All securities issued under the offering will be subject to a hold period expiring 4 months and 1 day after issuance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
none
News
Optimi Health To Host MDMA Educational Quality Assurance Webinar For Clinicians And Practitioners
Rhea-AI Summary
Optimi Health Corp. is hosting a webinar titled 'Know Your Drug Candidate: Safeguarding Quality in Psychedelic Therapy' to provide insights into the safety and quality standards of their psychedelic drug candidates. The company is the only end-to-end, publicly listed psychedelics company currently offering its drug candidates at scale to address accessibility through lower costs. The FDA is expected to decide on the acceptance of the New Drug Application for MDMA-Assisted Therapy for PTSD by February 12, 2024, which has the potential to reshape the industry landscape.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
conferences
Stock OPTHF logo
Optimi Health Corp

OTC:OPTHF

OPTHF Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

OPTHF Stock Data

16.30M
72.33M
17.55%
0.05%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Vancouver